Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
WikiMesothelioma — Mesothelioma Knowledge Base
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Pages for logged out editors
learn more
Contributions
Talk
Editing
Treatment Options
(section)
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Key Facts Box: 2025 Mesothelioma Treatment Statistics == {| class="wikitable" style="width:100%; border:2px solid #1a5276; border-collapse:collapse;" |- ! style="background:#1a5276; color:white; padding:12px; text-align:left;" colspan="2" | Essential Treatment and Cost Information |- | style="padding:10px; background:#f8f9fa; color:#333; border-bottom:1px solid #dee2e6; width:50%;" | '''Monthly Treatment Costs''' | style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" | $11,000-$12,000 average across all modalities |- | style="padding:10px; background:#ffffff; color:#333; border-bottom:1px solid #dee2e6;" | '''Immunotherapy Annual Cost''' | style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" | $150,000-$256,000 for nivolumab plus ipilimumab |- | style="padding:10px; background:#f8f9fa; color:#333; border-bottom:1px solid #dee2e6;" | '''P/D Surgery Survival''' | style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" | 21 months median with 2.2% 30-day mortality |- | style="padding:10px; background:#ffffff; color:#333; border-bottom:1px solid #dee2e6;" | '''CheckMate 743 Results''' | style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" | 18.1 months survival, 23% alive at 3 years |- | style="padding:10px; background:#f8f9fa; color:#333; border-bottom:1px solid #dee2e6;" | '''September 2024 FDA Approval''' | style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" | Pembrolizumab + chemotherapy (52% response rate) |- | style="padding:10px; background:#ffffff; color:#333; border-bottom:1px solid #dee2e6;" | '''Active Clinical Trials''' | style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" | 70+ trials recruiting in U.S. as of 2025 |- | style="padding:10px; background:#f8f9fa; color:#333; border-bottom:1px solid #dee2e6;" | '''Medicare Out-of-Pocket''' | style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" | ~$8,000 annual maximum |- | style="padding:10px; background:#ffffff; color:#333;" | '''Average Legal Settlement''' | style="padding:10px; color:#333;" | $1-$1.4 million (trust funds, lawsuits combined) |} ----
Summary:
Please note that all contributions to WikiMesothelioma — Mesothelioma Knowledge Base may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
WikiMesothelioma:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Treatment Options
(section)
Add topic